To evaluate the specificity and the potency of the TCR we co-cultured the TCR-transduced PBLs with cancer cell lines harboring KRASG12V mutations with or without transfection with HLA-A*11:01 (Fig. 3c) or with autologous DCs pulsed with a serial dilution of the mutated 9mer and wild-type peptides (Fig. 3d). The gene discussed is HLA-A; the disease is cancer.